secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001753926-25-000984
Event type: regulatory
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets
-----------------------------------------------------------------------------

- Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.
- Non-compliance with Listing Rules 5635(d) and 5640 due to Series C preferred and warrants issued in Dec 2024-Mar 2025 private placements.
- Common stock now quoted on OTC Markets under symbol LIPO; company exploring other listing venues.
- Company disappointed, states business fundamentals intact; continuing clinical development of LP-10 and LP-310.
- Lipella remains an SEC reporting company and will continue filing periodic reports.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000984/0001753926-25-000984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000984/g084852_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer